|
Item 1.01
|
Entry Into A Material Definitive Agreement.
|
Entry
into Securities Purchase Agreement and Issuance of Convertible Promissory Note
On
June 28, 2021, Oncotelic Therapeutics, Inc., formerly Mateon Therapeutics, Inc. (the “Company”), entered into a Securities
Purchase Agreement (the "SPA") with Geneva Roth Remark Holdings, Inc. ("Geneva"), pursuant to which
the Company issued to Geneva a Convertible Promissory Note (the "Geneva Note") in the amount of $103,750, on the same
terms and subject to the same conditions as set forth in the Securities Purchase Agreement and Convertible Promissory Note as disclosed
by the Company in its Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 1, 2021.
For
a description of the terms and conditions of the SPA and Geneva Note, see the Company's Current Report on Form 8-K, filed with the Securities
and Exchange Commission on June 1, 2021, for which the form of the SPA and Geneva Note were attached as Exhibit 10.1 and Exhibit 10.2,
respectively.
Extension
of Maturity Date for J.H. Darbie Financing Notes & Issuance of Oncotelic Warrants
As
previously disclosed in the Current Report on Form 8-K, filed with the Securities and Exchange Commission (“SEC”)
on July 23, 2020, and subsequently in the Current Report on Form 8-K filed with the SEC on March 26, 2021, the Company entered
into subscription agreements with certain accredited investors (the “Investors”), whereby the Company issued and sold
a total of 100 units (“Units”), with each Unit consisting of (i) 25,000 shares of the common stock, par value
$0.01 per share (“Edgepoint Common Stock”), of EdgePoint AI, Inc., a Delaware Corporation (“EdgePoint”),
a division of the Company, for a price of $1.00 per share of Edgepoint Common Stock; (ii) one convertible promissory note issued by the
Company (the “Note”), convertible into up to 25,000 shares of EdgePoint Common Stock at a conversion price of $1.00
per share, or up to 138,889 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”),
at a conversion price of $0.18 per share; and (iii) 100,000 warrants, consisting of (a) 50,000 warrants to purchase an equivalent number
of shares of EdgePoint Common Stock at $1.00 per share, and (b) 50,000 warrants to purchase an equivalent number of shares of Company
Common Stock at $0.20 per share (“Oncotelic Warrant”)(collectively, the “JH Darbie Financing”).
On
June 29, 2021, the Company and the Investors agreed to extend the maturity date of the Notes from June 30, 2021, to March 31, 2022. Additionally,
the Company will issue to the Investors an aggregate of 20.0 million additional Oncotelic Warrants, and 2.0 million additional Oncotelic
Warrants to J.H. Darbie & Co., Inc., as placement agent. Each Investor will be entitled to receive 200,000 additional Oncotelic Warrants
for each Unit purchased. For a description of the JH Darbie Financing and the Units sold thereunder, see the Company’s Current
Report on Form 8-K, filed with the Securities and Exchange Commission on July 23, 2020.